Agree. A significant step for Cynata and if the study goes well these multiple sites would serve as an important infrastructure for a confirmatory study and Cynata could then more easily apply for approval in multiple jurisdictions. I tend to agree with Col Re Capital Raise but more so towards end of 2024 unless they get a partnership agreement w upfront payment on one of their early stage assets DFU or Kidney which I think is a better avenue so they maintain focus, get help from Big Pharma and avoid significant capital dilution from a CR at low prices. I'd imagine they would have partnered GVHD prior to trial commencement if that was the objective and will now wait until results are published.
All hypotheticals. DYOR.
Agree. A significant step for Cynata and if the study goes well...
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.21M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 23.5¢ | 22.0¢ | $20.38K | 90.67K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 86380 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 12372 | 2 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
23.0¢ |
Change
0.000 ( 2.22 %) |
||||
| Open | High | Low | Volume | ||
| 23.0¢ | 23.0¢ | 23.0¢ | 10474 | ||
| Last updated 11.40am 09/05/2024 ? | |||||
| CYP (ASX) Chart |